Global Genes Rare Disease Stock Index Rises 2.88% During JPMorgan Week


The Global Genes Rare Disease Stock Index finished the week up 2.88 percent as investors focused on what was a suprisingly light news flow out of the closely watched JPMorgan Healthcare Conference. The Global Genes Index outperformed all of the other major indices during the week. 

INDEX2017 Close1/5/181/12/18Week ChangeYTD CHANGE
GLOBAL GENES RARE DISEASE STOCK INDEX1232.321235.771271.392.88%3.17%
NYSE ARCA PHARMA544.93559.01564.500.98%3.59%
DJIA24719.2225295.8725803.192.01%4.39%
S&P 5002673.612743.152786.241.57%4.21%
NASDAQ COMP6903.397136.567261.061.74%5.18%
NASDAQ BIOTECH3356.613454.083,522.911.99%4.95%

The Global Genes Rare Disease Stock Index is a price-weighted index of a representative sample of rare disease drug developers whose shares trade on U.S. exchanges. The index had a value of 1,000 on December 30, 2016. The components include Alexion Pharmaceuticals (ALXN), Amicus Therapeutics (FOLD), Audentes Therapeutics (BOLD), AveXis (AVXS), BioMarin Pharmaceutical (BMRN), bluebird Bio (BLUE), Corbus Pharmaceuticals (CRBP), Idera Pharmaceuticals (IDRA), Intercept Pharmaceuticals (ICPT), Ionis Pharmacecuticals (IONS), PTC Therapeutics (PTCT), Sarepta Therapeutics, Spark Theraeptuics (ONCE), and Ultragenyx Pharmaceutical (RARE). 

Filed Under: Business, Data Center, Global Genes

Speak Your Mind

*